Statin Use May Not Impact Prognosis of Patients With Follicular Lymphoma

Share this content:
Statin use may not impact the prognosis of patients with follicular lymphoma who are treated with immunochemotherapy.
Statin use may not impact the prognosis of patients with follicular lymphoma who are treated with immunochemotherapy.

Statin use may not impact the prognosis of patients with follicular lymphoma who are treated with immunochemotherapy, according to a study published in the American Journal of Hematology.1

Researchers led by Emmanuel Bachy, MD, of Claude Bernard University Lyon in France looked at 1135 participants who were enrolled in the PRIMA study in order to assess the outcome of patients with follicular lymphoma treated with immunochemotherapy according to the use of statins.

“An adverse prognostic impact of statin use in lymphoma was first suspected from in vitro data showing an impairment of anti-CD20 antibody binding,” the authors noted. “However, further clinical studies suggested an improved outcome associated with their use in hematological malignancies.”

Among the observed patients, 119 were on statins at the time of diagnosis. According to the use of statins, researchers evaluated for adverse events frequencies, event-free survival (EFS), time to next lymphoma treatment (TTNLT), time to next chemotherapy (TTNCT), and overall survival (OS).

RELATED: Everolimus Plus CHOP May Be Effective for Peripheral T-cell Lymphoma

The rate of overall and specific cardiovascular adverse events were comparable among all patients during induction and maintenance, while outcomes in terms of response rates or EFS, TTNLT, TTNCT and OS were similar regardless of statin use upon univariate and multivariate analyses.

Reference

  1. Bachy E, Estell JA, Van de Neste E, et al. Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: an exploratory analysis of the PRIMA cohort study [published online ahead of print January 22, 2016]. Am J Hematol. doi: 10.1002/ajh.24305.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters